0 (0%)		12-26 20:18
Open: High: Volume: 0		Pre. Close: Low: Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	519	1-year :	560.39
Resists	First :	444.35	Second :	479.79
Pivot price	406.43
Supports	First :	387.02	Second :	322
MAs	MA(5) :	401.58	MA(20) :	420.29
	MA(100) :	447.56	MA(250) :	0
MACD	MACD :	-13.5	Signal :	-13.2
%K %D	K(14,3) :	14.4	D(3) :	15.8
RSI	RSI(14): 38.9
52-week	High :	495.54	Low :	205.86

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ALNY ] has closed above bottom band by 41.4%. Bollinger Bands are 9.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	405.17 - 407.22	407.22 - 408.9
Low:	392.58 - 394.75	394.75 - 396.53
Close:	397.41 - 400.81	400.81 - 403.61

Mon, 22 Dec 2025
Alnylam Pharmaceuticals (ALNY) Valuation Check After NASDAQ-100 Entry and $250m Manufacturing Expansion - simplywall.st

Mon, 22 Dec 2025
Alnylam Pharmaceuticals (ALNY) Stock After Hours: Nasdaq-100 debut, fresh catalysts, and what to watch before Tuesday’s open (Dec. 23) - ts2.tech

Mon, 22 Dec 2025
Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook - ts2.tech

Mon, 22 Dec 2025
Alnylam Pharmaceuticals, Inc.(NasdaqGS: ALNY) added to NASDAQ-100 Index - marketscreener.com

Sun, 21 Dec 2025
CFOs Speak: Straight Talk From Chevron and a Biotech Pioneer - Bloomberg.com

Sun, 21 Dec 2025
118,800 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Congress Asset Management Co. - MarketBeat

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange:
Sector:
Industry:
Shares Out	132 (M)
Shares Float	130 (M)
Held by Insiders	1.4 (%)
Held by Institutions	100.2 (%)
Shares Short	3,960 (K)
Shares Short P.Month	3,770 (K)

EPS	0.31
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.76
Profit Margin	1.3 %
Operating Margin	29.4 %
Return on Assets (ttm)	3.6 %
Return on Equity (ttm)	32.7 %
Qtrly Rev. Growth	149.3 %
Gross Profit (p.s.)	20.36
Sales Per Share	24.29
EBITDA (p.s.)	2.42
Qtrly Earnings Growth	0 %
Operating Cash Flow	266 (M)
Levered Free Cash Flow	98 (M)

PE Ratio	1251.84
PEG Ratio	0
Price to Book value	226.32
Price to Sales	16.48
Price to Cash Flow	199.05

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.